Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
DRI Healthcare ( ($TSE:DHT.UN) ) has provided an update.
DRI Healthcare Trust has promoted Zaheed Mawani to the position of Chief Financial Officer, effective October 1, 2025. Mr. Mawani, who joined the company as Chief Compliance Officer in 2024, brings over 30 years of financial leadership experience from major public companies. This strategic move underscores DRI Healthcare’s commitment to leveraging internal talent for its growth. The outgoing CFO, Amit Kapur, will assist in a smooth transition until the end of September.
The most recent analyst rating on ($TSE:DHT.UN) stock is a Buy with a C$19.00 price target. To see the full list of analyst forecasts on DRI Healthcare stock, see the TSE:DHT.UN Stock Forecast page.
Spark’s Take on TSE:DHT.UN Stock
According to Spark, TipRanks’ AI Analyst, TSE:DHT.UN is a Outperform.
DRI Healthcare’s strong financial stability and recent positive corporate events, such as FDA approval and strategic internalization, are significant strengths. However, the high P/E ratio suggests potential overvaluation, and recent revenue declines pose profitability challenges. The technical indicators support a positive outlook, but valuation concerns and regulatory uncertainties temper the overall score.
To see Spark’s full report on TSE:DHT.UN stock, click here.
More about DRI Healthcare
DRI Healthcare is a leader in global pharmaceutical royalty monetization, having deployed over $3.0 billion since its inception in 1989. The company has acquired more than 75 royalties on over 45 drugs and is listed on the Toronto Stock Exchange under the symbols ‘DHT.UN’ and ‘DHT.U’.
Average Trading Volume: 37,154
Technical Sentiment Signal: Buy
Current Market Cap: C$812.5M
See more data about DHT.UN stock on TipRanks’ Stock Analysis page.